We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Crown Bioscience expands U.K. facilities

Crown Bioscience expands U.K. facilities

December 3, 2015
CenterWatch Staff

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has significantly increased the capacity of its U.K. facilities.

The expansion has been driven by client demand and coincides with the establishment of an expanded panel of immuno-oncology services at Crown Bioscience’s European base, including bioluminescent imaging of popular syngeneic cell line models.

“This is yet another example of Crown Bioscience’s continued success and overall growth as well as our commitment to meet the needs of our European clients,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience. “This expansion, both in terms of capacity and personnel, will help us accommodate the huge industry demand for syngeneic models, and also provide us with the capacity we need to continue to introduce new oncology models that researchers demand.”

The expansion enables Crown Bioscience to diversify its global portfolio of syngeneic models into orthotopic variants. The U.K. team has an established focus on hormone-associated cancers, such as prostate and breast cancer.

Global News CROs/Service Providers

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing